Emergent BioSolutions, Inc.
400 Professional Drive
About Emergent BioSolutions, Inc.
Emergent BioSolutions Inc. is a biopharmaceutical company focused on the development, manufacture and commercialization of vaccines and therapeutics that assist the body’s immune system to prevent or treat disease. Emergent’s marketed product, BioThrax® (Anthrax Vaccine Adsorbed), is the only vaccine licensed by the U.S. Food and Drug Administration for the prevention of anthrax infection. Emergent’s development pipeline includes programs focused on anthrax, botulism, tuberculosis, typhoid, hepatitis B and chlamydia.
455 articles with Emergent BioSolutions, Inc.
Vaxart Announces It Entered Into An Agreement With Emergent Biosolutions For The Development And Manufacturing Of Oral Coronavirus (Covid-19) Vaccine Candidate
Oral Vaccines based on Proprietary VAAST™ Platform Offer Potential Key Advantages in Global Quest to Develop Coronavirus Vaccine
Emergent Biosolutions Signs Development And Manufacturing Agreement With Vaxart For Their Experimental Oral Vaccine Candidate For Coronavirus Disease
Emergent BioSolutions Inc. announced that it has entered into an agreement with Vaxart, Inc., a clinical-stage biotechnology company, whereby Emergent has agreed to utilize its molecule-to-market contract development and manufacturing services to develop and manufacture Vaxart’s experimental oral vaccine candidate for coronavirus disease.
Emergent BioSolutions Initiates Development of Plasma-Derived Product Candidates for the Treatment and Prevention of Coronavirus Disease
Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has initiated development of two product candidates for the treatment and prevention of coronavirus disease (COVID-19).
Emergent BioSolutions Signs Development and Manufacturing Agreement With Novavax for Experimental Vaccine Candidate for Coronavirus Disease
Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has entered into an agreement with Novavax, Inc. (NASDAQ:NVAX) whereby Emergent will collaborate with Novavax, utilizing its molecule-to-market contract development and manufacturing (CDMO) services to support bringing into the clinic Novavax’s novel experimental vaccine candidate to protect against coronavirus disease (COVID-19).
Axiom Real-Time Metrics (“Axiom”), premier provider of unified eClinical solutions and services is pleased to announce its engagement with Emergent BioSolutions (NYSE: EBS), a global life sciences company whose mission is to protect and enhance life by providing specialty products and contract development and manufacturing services that address public health threats.
GAITHERSBURG, Md., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) reported financial results for the quarter and year ended December 31, 2019. FINANCIAL HIGHLIGHTS (in millions) Q4 2019 (unaudited) Q4 2018 (unaudited) $ Change % Change Total Revenues $360.4 $270.7 $89.7 33.1% Pre-tax Income 71.5 3.6 67.9 * Net Income 46.9 (3.4) 50.3 * Adjusted Net Income (1) 82.7 39.5 43.2 109.4% EBITDA (1) 107.9 36.1 71.8 198.9% Adjust
Emergent BioSolutions to Release Fourth Quarter and Full Year 2019 Financial Results and Conduct a Conference Call on February 20, 2020
Emergent BioSolutions Inc. will host a conference call on Thursday, February 20, 2020 at 5:00 pm to discuss the financial results for the fourth quarter and full year 2019, recent business developments, financial outlook for full year 2020, and revenue guidance for the first quarter of 2020..
Emergent BioSolutions Receives EMA Agreement for Proposed Development Path of Investigational Chikungunya VLP Vaccine Candidate
Emergent BioSolutions Inc. announced that it has received agreement from the European Medicines Agency to pursue its proposed development plan for its chikungunya virus virus-like particle vaccine candidate.
Emergent BioSolutions Announces Preliminary 2019 Financial Results and Provides 2020 Financial Forecast
Emergent BioSolutions Inc. announced selected preliminary unaudited 2019 financial results and its financial forecast for 2020.
Emergent BioSolutions Inc. announced that members of the company’s executive management team will participate in the following investor conferences during the first quarter of 2020
Emergent BioSolutions Board Members Dr. Sue Bailey and Dr. Kathryn C. Zoon Named Most Influential Corporate Directors
Emergent BioSolutions Inc. (NYSE: EBS) today announced that two members of its board of directors – Dr. Sue Bailey and Dr. Kathryn C. Zoon – have been recognized as WomenInc. magazine's 2019 Most Influential Corporate Directors.
Emergent BioSolutions Presents Positive Immunogenicity Results From Phase 2 Study of Its Investigational Chikungunya VLP Vaccine Candidate
Emergent BioSolutions Inc. (NYSE:EBS) announced updated results from the interim analysis of its Phase 2 clinical study evaluating the safety and immunogenicity of the company’s chikungunya virus virus-like particle (CHIKV VLP) vaccine candidate across a series of dosing regimens
Emergent BioSolutions Announces Growth Strategy and 2024 Goals at Analyst and Investor DayCompany aspires to exceed $2 billion in revenue with 27%-30% adjusted EBITDA margin by year end 2024
Emergent’s senior management shared their vision for continuing to build leadership positions in select public health threat markets and contract development and manufacturing, leveraging the company’s unique set of assets, and realizing sustained financial performance and shareholder value creation.
Emergent BioSolutions Reports Financial Results for Third Quarter and Nine Months Ended September 30, 2019
Emergent BioSolutions Inc. (NYSE: EBS) reported financial results for the third quarter and nine months ended September 30, 2019.
Emergent BioSolutions Inc. announced that the company will host an analyst and investor day on November 21, 2019 in New York City.
Emergent BioSolutions Receives EMA Prime Designation for Its Chikungunya Virus VLP Vaccine Candidate
Emergent BioSolutions Inc. (NYSE:EBS) today announced that the company’s chikungunya virus (CHIKV) virus-like particle (VLP) vaccine candidate, CHIKV VLP, was granted PRIority MEdicines, or PRIME, designation by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) during its September meeting.
Although bioterrorism doesn’t get the kind of attention more traditional bombings and shootings receive, the biotech industry and the federal government are paying attention and actively funding and developing countermeasures to potential bioterror, military and public health emergencies.
Politicians might deny climate change, but disease-carrying insects and their pathogens aren’t—they’re exploiting it.
Touting that it is helping fight the opioid epidemic, Emergent BioSolutions is acquiring Adapt Pharma. Under the terms of the deal, Emergent will pay $635 million up front and up to $100 million in cash for various sales-based milestones through 2022.
CEPI Awards Contract Worth up to $36 Million to Profectus BioSciences and Emergent BioSolutions to Develop Lassa Virus Vaccine
CEPI (the Coalition for Epidemic Preparedness Innovations) today announced a new collaboration with Profectus BioSciences, Inc. and Emergent BioSolutions Inc. (NYSE: EBS) under which they will receive up to USD $36 million to advance the development and manufacture of a vaccine against the Lassa virus—an estimated 100,000 to 300,000 cases of Lassa virus infection occur each year.1